Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739931 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
A Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT03739931: Completed Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, sponsored by ModernaTX.
NCT03739931 is a Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma that has completed, run by ModernaTX. The registered enrollment target is 134 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03739931, a Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL mRNA-2752
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Cancer Center at Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- NYU Langone Medical Center - New York
- Icahn School of Medicine at Mount Sinai - New York
- James P. Wilmot Cancer Center - Rochester
Other
- Alfred Health - Melbourne
- Westmead Hospital - Westmead
- Melanoma Institute of Australia - Wollstonecraft
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Providence St. John's Health Center - Santa Monica
Colorado
- University of Colorado Denver - Aurora
Connecticut
- Yale Cancer Center - New Haven
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Sarasota
Illinois
- The University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
What the finished NCT03739931 record still lists
NCT03739931 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (123% higher).
The record links to 2 conditions, with Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT03739931 names 20 study sites across 13 states, led by Massachusetts, New York, Other.
Frequently Asked Questions
What is clinical trial NCT03739931 about?
NCT03739931 is a clinical study titled "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies". The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
What is the current status of trial NCT03739931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2018-11-27. Estimated completion is 2025-08-01.
What conditions does trial NCT03739931 study?
This clinical trial studies the following conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma.
What interventions are being tested in trial NCT03739931?
The interventions under investigation include: Durvalumab (BIOLOGICAL), mRNA-2752 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03739931?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739931 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03739931's enrollment target sits among peer trials
134 427th of 2000 higher than 1,569 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI